SK125999A3 - Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors - Google Patents
Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors Download PDFInfo
- Publication number
- SK125999A3 SK125999A3 SK1259-99A SK125999A SK125999A3 SK 125999 A3 SK125999 A3 SK 125999A3 SK 125999 A SK125999 A SK 125999A SK 125999 A3 SK125999 A3 SK 125999A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alloy
- phenyl
- chromium
- pyrrolo
- pyrimidin
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title description 2
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
- -1 2-phenyl-1,3-dioxan-5-yl Chemical group 0.000 claims abstract description 241
- 150000001875 compounds Chemical class 0.000 claims abstract description 177
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 122
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 56
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 50
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 20
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 10
- 230000002062 proliferating effect Effects 0.000 claims abstract description 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 9
- 125000005544 phthalimido group Chemical group 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 187
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 34
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 33
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 32
- 239000012071 phase Substances 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 29
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 27
- 239000006185 dispersion Substances 0.000 claims description 26
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000010410 layer Substances 0.000 claims description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 21
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 229910021529 ammonia Inorganic materials 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
- NFSWHYRUVWRUDN-UHFFFAOYSA-N 5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2NC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 NFSWHYRUVWRUDN-UHFFFAOYSA-N 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 6
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004146 Propane-1,2-diol Substances 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- LYBNLOMPRHYDRF-UHFFFAOYSA-N 2-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1O LYBNLOMPRHYDRF-UHFFFAOYSA-N 0.000 claims description 2
- PIJBBYHMSXEZMC-UHFFFAOYSA-N 5-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-2-nitrobenzoic acid Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 PIJBBYHMSXEZMC-UHFFFAOYSA-N 0.000 claims description 2
- SMKWVLYWUQBZKW-UHFFFAOYSA-N 5-[4-(benzenesulfinyl)phenyl]-7-tert-butylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1S(=O)C1=CC=CC=C1 SMKWVLYWUQBZKW-UHFFFAOYSA-N 0.000 claims description 2
- PAHKLGUKLSFIBQ-UHFFFAOYSA-N 7-cyclopentyl-5-(2-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C1=CC=CC=C1OC1=CC=CC=C1 PAHKLGUKLSFIBQ-UHFFFAOYSA-N 0.000 claims description 2
- ISMWZGJUONENAM-UHFFFAOYSA-N 7-tert-butyl-5-(4-phenylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1C1=CC=CC=C1 ISMWZGJUONENAM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005543 phthalimide group Chemical group 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims 126
- 239000000956 alloy Substances 0.000 claims 126
- 239000011651 chromium Substances 0.000 claims 119
- 229910052804 chromium Inorganic materials 0.000 claims 55
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 53
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims 39
- 230000003647 oxidation Effects 0.000 claims 38
- 238000007254 oxidation reaction Methods 0.000 claims 38
- 229910000423 chromium oxide Inorganic materials 0.000 claims 34
- 229910052751 metal Inorganic materials 0.000 claims 24
- 239000002184 metal Substances 0.000 claims 24
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 21
- 229910052721 tungsten Inorganic materials 0.000 claims 19
- 238000005260 corrosion Methods 0.000 claims 18
- 230000007797 corrosion Effects 0.000 claims 18
- 239000011521 glass Substances 0.000 claims 18
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims 17
- 229910052750 molybdenum Inorganic materials 0.000 claims 16
- 239000002243 precursor Substances 0.000 claims 16
- 239000010937 tungsten Substances 0.000 claims 16
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 15
- 230000000052 comparative effect Effects 0.000 claims 14
- 239000011733 molybdenum Substances 0.000 claims 14
- 239000006060 molten glass Substances 0.000 claims 13
- 238000005245 sintering Methods 0.000 claims 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 10
- 230000001590 oxidative effect Effects 0.000 claims 10
- VNNRSPGTAMTISX-UHFFFAOYSA-N chromium nickel Chemical compound [Cr].[Ni] VNNRSPGTAMTISX-UHFFFAOYSA-N 0.000 claims 8
- 229910052742 iron Inorganic materials 0.000 claims 8
- 238000001757 thermogravimetry curve Methods 0.000 claims 8
- 229910052759 nickel Inorganic materials 0.000 claims 7
- 238000002161 passivation Methods 0.000 claims 7
- 239000011241 protective layer Substances 0.000 claims 7
- 239000003870 refractory metal Substances 0.000 claims 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 6
- 238000000137 annealing Methods 0.000 claims 6
- 239000000835 fiber Substances 0.000 claims 6
- 229910018487 Ni—Cr Inorganic materials 0.000 claims 5
- 229910052786 argon Inorganic materials 0.000 claims 5
- 229940117975 chromium trioxide Drugs 0.000 claims 5
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 claims 5
- 229910017052 cobalt Inorganic materials 0.000 claims 5
- 239000010941 cobalt Substances 0.000 claims 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 5
- 229910000753 refractory alloy Inorganic materials 0.000 claims 5
- 230000035882 stress Effects 0.000 claims 5
- 239000002344 surface layer Substances 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000003628 erosive effect Effects 0.000 claims 4
- 238000007731 hot pressing Methods 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052763 palladium Inorganic materials 0.000 claims 4
- 230000009471 action Effects 0.000 claims 3
- 238000005516 engineering process Methods 0.000 claims 3
- 239000003365 glass fiber Substances 0.000 claims 3
- 239000011491 glass wool Substances 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- 238000011065 in-situ storage Methods 0.000 claims 3
- 239000011261 inert gas Substances 0.000 claims 3
- 238000005551 mechanical alloying Methods 0.000 claims 3
- 150000002736 metal compounds Chemical class 0.000 claims 3
- 229910052758 niobium Inorganic materials 0.000 claims 3
- 239000010955 niobium Substances 0.000 claims 3
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims 3
- 238000003825 pressing Methods 0.000 claims 3
- 229910052715 tantalum Inorganic materials 0.000 claims 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 3
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 229910052684 Cerium Inorganic materials 0.000 claims 2
- 229910000684 Cobalt-chrome Inorganic materials 0.000 claims 2
- 229910052776 Thorium Inorganic materials 0.000 claims 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims 2
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 claims 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims 2
- AXTNPHLCOKUMDY-UHFFFAOYSA-N chromium cobalt Chemical compound [Co][Cr][Co] AXTNPHLCOKUMDY-UHFFFAOYSA-N 0.000 claims 2
- SZMZREIADCOWQA-UHFFFAOYSA-N chromium cobalt nickel Chemical compound [Cr].[Co].[Ni] SZMZREIADCOWQA-UHFFFAOYSA-N 0.000 claims 2
- UPHIPHFJVNKLMR-UHFFFAOYSA-N chromium iron Chemical compound [Cr].[Fe] UPHIPHFJVNKLMR-UHFFFAOYSA-N 0.000 claims 2
- OYSYRRRAJPTBHI-UHFFFAOYSA-N chromium molybdenum tungsten Chemical compound [Cr][W][Mo] OYSYRRRAJPTBHI-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000010952 cobalt-chrome Substances 0.000 claims 2
- 238000007596 consolidation process Methods 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- 238000005242 forging Methods 0.000 claims 2
- 239000010439 graphite Substances 0.000 claims 2
- 229910002804 graphite Inorganic materials 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 229910052735 hafnium Inorganic materials 0.000 claims 2
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 229910052746 lanthanum Inorganic materials 0.000 claims 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 239000004570 mortar (masonry) Substances 0.000 claims 2
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 claims 2
- 238000005121 nitriding Methods 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 230000002787 reinforcement Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000006104 solid solution Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000004753 textile Substances 0.000 claims 2
- 238000009827 uniform distribution Methods 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 238000003466 welding Methods 0.000 claims 2
- 229910052726 zirconium Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 229910000714 At alloy Inorganic materials 0.000 claims 1
- HJJXVPUOMJYVPN-UHFFFAOYSA-N C1(CCCC1)N1C=C(C2=C1N=CN=C2N)C2=CC=C(C=C2)OC2=CC=CC=C2.C(C)(C)N2C=C(C1=C2N=CN=C1N)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound C1(CCCC1)N1C=C(C2=C1N=CN=C2N)C2=CC=C(C=C2)OC2=CC=CC=C2.C(C)(C)N2C=C(C1=C2N=CN=C1N)C1=CC=C(C=C1)OC1=CC=CC=C1 HJJXVPUOMJYVPN-UHFFFAOYSA-N 0.000 claims 1
- 229910000531 Co alloy Inorganic materials 0.000 claims 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- 229910000990 Ni alloy Inorganic materials 0.000 claims 1
- 229910000831 Steel Inorganic materials 0.000 claims 1
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 claims 1
- WBWJXRJARNTNBL-UHFFFAOYSA-N [Fe].[Cr].[Co] Chemical compound [Fe].[Cr].[Co] WBWJXRJARNTNBL-UHFFFAOYSA-N 0.000 claims 1
- RMXTYBQNQCQHEU-UHFFFAOYSA-N ac1lawpn Chemical compound [Cr]#[Cr] RMXTYBQNQCQHEU-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000005275 alloying Methods 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000000919 ceramic Substances 0.000 claims 1
- BIJOYKCOMBZXAE-UHFFFAOYSA-N chromium iron nickel Chemical compound [Cr].[Fe].[Ni] BIJOYKCOMBZXAE-UHFFFAOYSA-N 0.000 claims 1
- VNTLIPZTSJSULJ-UHFFFAOYSA-N chromium molybdenum Chemical compound [Cr].[Mo] VNTLIPZTSJSULJ-UHFFFAOYSA-N 0.000 claims 1
- NVIVJPRCKQTWLY-UHFFFAOYSA-N cobalt nickel Chemical compound [Co][Ni][Co] NVIVJPRCKQTWLY-UHFFFAOYSA-N 0.000 claims 1
- XTUHPOUJWWTMNC-UHFFFAOYSA-N cobalt(2+);dioxido(dioxo)chromium Chemical class [Co+2].[O-][Cr]([O-])(=O)=O XTUHPOUJWWTMNC-UHFFFAOYSA-N 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 239000005356 container glass Substances 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000005485 electric heating Methods 0.000 claims 1
- 238000000840 electrochemical analysis Methods 0.000 claims 1
- 238000002848 electrochemical method Methods 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 238000009776 industrial production Methods 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 229910000765 intermetallic Inorganic materials 0.000 claims 1
- 238000000462 isostatic pressing Methods 0.000 claims 1
- 238000005297 material degradation process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229910001092 metal group alloy Inorganic materials 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 238000004452 microanalysis Methods 0.000 claims 1
- 239000002557 mineral fiber Substances 0.000 claims 1
- 229910001120 nichrome Inorganic materials 0.000 claims 1
- 229910000480 nickel oxide Inorganic materials 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 238000013021 overheating Methods 0.000 claims 1
- 229910001175 oxide dispersion-strengthened alloy Inorganic materials 0.000 claims 1
- SIWVEOZUMHYXCS-UHFFFAOYSA-N oxo(oxoyttriooxy)yttrium Chemical compound O=[Y]O[Y]=O SIWVEOZUMHYXCS-UHFFFAOYSA-N 0.000 claims 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 claims 1
- 150000002927 oxygen compounds Chemical class 0.000 claims 1
- 238000010587 phase diagram Methods 0.000 claims 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 238000007780 powder milling Methods 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 238000006479 redox reaction Methods 0.000 claims 1
- 239000011819 refractory material Substances 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 229910000601 superalloy Inorganic materials 0.000 claims 1
- 230000008646 thermal stress Effects 0.000 claims 1
- 238000003826 uniaxial pressing Methods 0.000 claims 1
- 210000002268 wool Anatomy 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
- RUDFQVOCFDJEEF-UHFFFAOYSA-N yttrium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Y+3].[Y+3] RUDFQVOCFDJEEF-UHFFFAOYSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 172
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 52
- 239000007787 solid Substances 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 238000003756 stirring Methods 0.000 description 26
- 239000000377 silicon dioxide Substances 0.000 description 25
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 22
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000010992 reflux Methods 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000011928 denatured alcohol Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 11
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000002024 ethyl acetate extract Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- RAXTYMXDSNWNJS-UHFFFAOYSA-N 2-bromo-1-(4-phenoxyphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1OC1=CC=CC=C1 RAXTYMXDSNWNJS-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- PJIYFOYIHIDOJN-UHFFFAOYSA-N 4-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopent-2-en-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C2C=CC(O)C2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 PJIYFOYIHIDOJN-UHFFFAOYSA-N 0.000 description 4
- KJHYDYATVCGFKG-UHFFFAOYSA-N 4-chloro-5-iodo-7-propan-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2N(C(C)C)C=C(I)C2=C1Cl KJHYDYATVCGFKG-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000006201 parenteral dosage form Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- OZSXUVWJCWELFF-UHFFFAOYSA-N 4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenol Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C1=CC=C(O)C=C1 OZSXUVWJCWELFF-UHFFFAOYSA-N 0.000 description 3
- VVJNBQCLBXPLKC-UHFFFAOYSA-N 4-(4-chloro-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)aniline Chemical compound C12=C(Cl)N=CN=C2N(C(C)C)C=C1C1=CC=C(N)C=C1 VVJNBQCLBXPLKC-UHFFFAOYSA-N 0.000 description 3
- SZBOWPMFRHBAES-UHFFFAOYSA-N 4-chloro-7-cyclopentyl-5-iodopyrrolo[2,3-d]pyrimidine Chemical compound C1=C(I)C=2C(Cl)=NC=NC=2N1C1CCCC1 SZBOWPMFRHBAES-UHFFFAOYSA-N 0.000 description 3
- CIHPWICLKKWTAY-UHFFFAOYSA-N 7-tert-butyl-5-(4-phenylsulfanylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1SC1=CC=CC=C1 CIHPWICLKKWTAY-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229960003540 oxyquinoline Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- WIKBZUXHNPONPP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-iodo-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(I)(C(F)(F)F)C(F)(F)F WIKBZUXHNPONPP-UHFFFAOYSA-N 0.000 description 2
- DJNIFZYQFLFGDT-UHFFFAOYSA-N 1-(4-phenoxyphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1OC1=CC=CC=C1 DJNIFZYQFLFGDT-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- SUGIXUOLQCWZSX-UHFFFAOYSA-N 2-amino-1-tert-butyl-4-(4-phenoxyphenyl)pyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 SUGIXUOLQCWZSX-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- GKNORMADYXCWRJ-UHFFFAOYSA-N 4-[4-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound C1=2C(N)=NC=NC=2NC=C1C(C=C1)=CC=C1OC1=CC=C(O)C=C1 GKNORMADYXCWRJ-UHFFFAOYSA-N 0.000 description 2
- DLJBKUOXIIRHOS-UHFFFAOYSA-N 4-chloro-5-(4-methoxyphenyl)-7-propan-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=CN(C(C)C)C2=NC=NC(Cl)=C12 DLJBKUOXIIRHOS-UHFFFAOYSA-N 0.000 description 2
- MDEAPLPJVDTMSN-UHFFFAOYSA-N 4-chloro-5-(4-nitrophenyl)-7-propan-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound C12=C(Cl)N=CN=C2N(C(C)C)C=C1C1=CC=C([N+]([O-])=O)C=C1 MDEAPLPJVDTMSN-UHFFFAOYSA-N 0.000 description 2
- KYDZEZNYRFJCSA-UHFFFAOYSA-N 4-tert-butylbenzenesulfonamide Chemical compound CC(C)(C)C1=CC=C(S(N)(=O)=O)C=C1 KYDZEZNYRFJCSA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- PIONBRMJOSUEHB-UHFFFAOYSA-N 5-(4-aminophenyl)-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C1=CC=C(N)C=C1 PIONBRMJOSUEHB-UHFFFAOYSA-N 0.000 description 2
- KTGZCXGZOLDVSP-UHFFFAOYSA-N 5-(4-methoxyphenyl)-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=CN(C(C)C)C2=NC=NC(N)=C12 KTGZCXGZOLDVSP-UHFFFAOYSA-N 0.000 description 2
- ITJWOPPSOKMWCK-UHFFFAOYSA-N 5-[4-(2-aminophenoxy)phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1N ITJWOPPSOKMWCK-UHFFFAOYSA-N 0.000 description 2
- PWEMILVNKQAISL-UHFFFAOYSA-N 5-[4-(2-nitrophenoxy)phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1[N+]([O-])=O PWEMILVNKQAISL-UHFFFAOYSA-N 0.000 description 2
- QJSJCFHSACXKCC-UHFFFAOYSA-N 5-[4-(4-aminophenoxy)phenyl]-7-tert-butylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C(N)C=C1 QJSJCFHSACXKCC-UHFFFAOYSA-N 0.000 description 2
- KNDIBTBKZBMNBL-UHFFFAOYSA-N 6-chloro-7-cyclopentyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=C(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C=2C(N)=NC=NC=2N1C1CCCC1 KNDIBTBKZBMNBL-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical class NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- YXEKEVOINGFDHV-UHFFFAOYSA-N 7-tert-butyl-5-(4-iodophenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C1=CC=C(I)C=C1 YXEKEVOINGFDHV-UHFFFAOYSA-N 0.000 description 2
- MYSJNRWPLKEUQT-UHFFFAOYSA-N 7-tert-butyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 MYSJNRWPLKEUQT-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 101150093908 PDGFRB gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- FMETVQKSDIOGPX-UHFFFAOYSA-N RK-24466 Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 FMETVQKSDIOGPX-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- DLDIDQIZPBIVNQ-UHFFFAOYSA-N hydron;2-methylpropan-2-amine;chloride Chemical compound Cl.CC(C)(C)N DLDIDQIZPBIVNQ-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- JTUVMRUPITZIEE-UHFFFAOYSA-N n-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxyphenyl]-4-chlorobenzamide Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C(C=C1O)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 JTUVMRUPITZIEE-UHFFFAOYSA-N 0.000 description 2
- CQVAFFLGWYZWPH-UHFFFAOYSA-N n-[4-(4-chloro-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide Chemical compound C12=C(Cl)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=C1 CQVAFFLGWYZWPH-UHFFFAOYSA-N 0.000 description 2
- NTBAONGQXIYCBE-UHFFFAOYSA-N n-[4-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 NTBAONGQXIYCBE-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 239000012485 toluene extract Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- HIZVCIIORGCREW-UHFFFAOYSA-N 1,4-dioxene Chemical compound C1COC=CO1 HIZVCIIORGCREW-UHFFFAOYSA-N 0.000 description 1
- UGRMITBWUVWUEB-UHFFFAOYSA-N 1-$l^{1}-oxidanyl-3-methylbenzene Chemical group CC1=CC=CC([O])=C1 UGRMITBWUVWUEB-UHFFFAOYSA-N 0.000 description 1
- HZRAUMRZKGXMEL-UHFFFAOYSA-N 1-[4-(4-methoxyphenoxy)phenyl]-3,3-dimethylbutan-1-one;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1OC1=CC=C(C(=O)CC(C)(C)C)C=C1 HZRAUMRZKGXMEL-UHFFFAOYSA-N 0.000 description 1
- ICXPZMQQZWKKMN-UHFFFAOYSA-N 1-[4-(4-methoxyphenoxy)phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C(C)=O)C=C1 ICXPZMQQZWKKMN-UHFFFAOYSA-N 0.000 description 1
- RRWFUWRLNIZICP-UHFFFAOYSA-N 1-bromo-2-phenoxybenzene Chemical compound BrC1=CC=CC=C1OC1=CC=CC=C1 RRWFUWRLNIZICP-UHFFFAOYSA-N 0.000 description 1
- AHDAKFFMKLQPTD-UHFFFAOYSA-N 1-bromo-3-phenoxybenzene Chemical compound BrC1=CC=CC(OC=2C=CC=CC=2)=C1 AHDAKFFMKLQPTD-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 1
- LZDMQFOLXJUDLT-UHFFFAOYSA-N 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-(3-chlorophenoxy)benzamide Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)C(N)=O)=CC=C1OC1=CC=CC(Cl)=C1 LZDMQFOLXJUDLT-UHFFFAOYSA-N 0.000 description 1
- FXJMGPTUCHENMZ-UHFFFAOYSA-N 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-(3-chlorophenoxy)phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)O)=CC=C1OC1=CC=CC(Cl)=C1 FXJMGPTUCHENMZ-UHFFFAOYSA-N 0.000 description 1
- PCIKKNSDIXLMOX-UHFFFAOYSA-N 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-phenoxybenzamide Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)C(N)=O)=CC=C1OC1=CC=CC=C1 PCIKKNSDIXLMOX-UHFFFAOYSA-N 0.000 description 1
- RRLZPBGVTUNYLG-UHFFFAOYSA-N 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-phenoxyphenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)O)=CC=C1OC1=CC=CC=C1 RRLZPBGVTUNYLG-UHFFFAOYSA-N 0.000 description 1
- QHBJFDHGXHZZSG-UHFFFAOYSA-N 2-(tert-butylamino)-1-(4-iodophenyl)ethanone;hydrochloride Chemical compound Cl.CC(C)(C)NCC(=O)C1=CC=C(I)C=C1 QHBJFDHGXHZZSG-UHFFFAOYSA-N 0.000 description 1
- ZHKCKKMMBOHRCY-UHFFFAOYSA-N 2-(tert-butylamino)-1-(4-phenoxyphenyl)ethanone;hydrochloride Chemical compound Cl.C1=CC(C(=O)CNC(C)(C)C)=CC=C1OC1=CC=CC=C1 ZHKCKKMMBOHRCY-UHFFFAOYSA-N 0.000 description 1
- HXEJQDISGVLYOE-UHFFFAOYSA-N 2-(tert-butylamino)-1-phenylethanone hydrochloride Chemical compound Cl.C(C)(C)(C)NCC(=O)C1=CC=CC=C1 HXEJQDISGVLYOE-UHFFFAOYSA-N 0.000 description 1
- ZCBPGURKZDCEFP-UHFFFAOYSA-N 2-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-5-nitrobenzoic acid Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1C(O)=O ZCBPGURKZDCEFP-UHFFFAOYSA-N 0.000 description 1
- MNBVQSKOALBMNJ-UHFFFAOYSA-N 2-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1O MNBVQSKOALBMNJ-UHFFFAOYSA-N 0.000 description 1
- XBTDIGWGOZVBHQ-UHFFFAOYSA-N 2-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C2C(CCC2)O)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XBTDIGWGOZVBHQ-UHFFFAOYSA-N 0.000 description 1
- AFGOFEFLRMONQO-UHFFFAOYSA-N 2-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]ethanol Chemical compound C1=2C(N)=NC=NC=2N(CCO)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 AFGOFEFLRMONQO-UHFFFAOYSA-N 0.000 description 1
- TTXCWPOHPCLUKB-UHFFFAOYSA-N 2-amino-1-(2,2-dimethylpropyl)-4-(4-phenoxyphenyl)pyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(CC(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 TTXCWPOHPCLUKB-UHFFFAOYSA-N 0.000 description 1
- JVDBMLDMYRQVGN-UHFFFAOYSA-N 2-amino-1-cyclopentyl-4-(4-phenoxyphenyl)pyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=CN1C1CCCC1 JVDBMLDMYRQVGN-UHFFFAOYSA-N 0.000 description 1
- OOQSGVDLFZSRGV-UHFFFAOYSA-N 2-amino-1-tert-butyl-4-(4-iodophenyl)pyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(C(C)(C)C)C=C1C1=CC=C(I)C=C1 OOQSGVDLFZSRGV-UHFFFAOYSA-N 0.000 description 1
- JWCOVNSHDJQAIO-UHFFFAOYSA-N 2-amino-1-tert-butyl-4-(4-phenylphenyl)pyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(C(C)(C)C)C=C1C1=CC=C(C=2C=CC=CC=2)C=C1 JWCOVNSHDJQAIO-UHFFFAOYSA-N 0.000 description 1
- KTEZZZQHUOYMMY-UHFFFAOYSA-N 2-amino-1-tert-butyl-4-(4-phenylsulfanylphenyl)pyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(C(C)(C)C)C=C1C(C=C1)=CC=C1SC1=CC=CC=C1 KTEZZZQHUOYMMY-UHFFFAOYSA-N 0.000 description 1
- ACWKUXDGUMRIPU-UHFFFAOYSA-N 2-amino-4-(4-phenoxyphenyl)-1-propan-2-ylpyrrole-3-carbonitrile Chemical compound N#CC1=C(N)N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 ACWKUXDGUMRIPU-UHFFFAOYSA-N 0.000 description 1
- XEHFZDUXNKNEFZ-UHFFFAOYSA-N 2-bromo-1-(4-phenylphenyl)ethanethione Chemical compound C1=CC(C(=S)CBr)=CC=C1C1=CC=CC=C1 XEHFZDUXNKNEFZ-UHFFFAOYSA-N 0.000 description 1
- KGHGZRVXCKCJGX-UHFFFAOYSA-N 2-bromo-1-(4-phenylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1C1=CC=CC=C1 KGHGZRVXCKCJGX-UHFFFAOYSA-N 0.000 description 1
- NPNXBJDANGZWOC-UHFFFAOYSA-N 2-bromo-1-[4-(4-methoxyphenoxy)phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C(=O)CBr)C=C1 NPNXBJDANGZWOC-UHFFFAOYSA-N 0.000 description 1
- LJKQIBWZNUCGSG-UHFFFAOYSA-N 2-chloro-1-(4-iodophenyl)ethanone Chemical compound ClCC(=O)C1=CC=C(I)C=C1 LJKQIBWZNUCGSG-UHFFFAOYSA-N 0.000 description 1
- ICXSHFWYCHJILC-UHFFFAOYSA-N 2-fluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1F ICXSHFWYCHJILC-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- VBTSHXSAHIROEH-UHFFFAOYSA-N 3-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenoxy]benzamide Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1Cl)=CC=C1OC1=CC=CC(C(N)=O)=C1 VBTSHXSAHIROEH-UHFFFAOYSA-N 0.000 description 1
- NLZQYHOBUFFEFE-UHFFFAOYSA-N 3-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenoxy]phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1Cl)=CC=C1OC1=CC=CC(O)=C1 NLZQYHOBUFFEFE-UHFFFAOYSA-N 0.000 description 1
- KWIISVZUQXBHMT-UHFFFAOYSA-N 3-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC(O)=C1 KWIISVZUQXBHMT-UHFFFAOYSA-N 0.000 description 1
- UJWXPHLWGVGIBB-UHFFFAOYSA-N 3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C2CC(O)CC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 UJWXPHLWGVGIBB-UHFFFAOYSA-N 0.000 description 1
- INEUGWBFDCYOPZ-UHFFFAOYSA-N 3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]propane-1,2-diol Chemical compound C1=2C(N)=NC=NC=2N(CC(O)CO)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 INEUGWBFDCYOPZ-UHFFFAOYSA-N 0.000 description 1
- IALBWOKSRZOBDJ-UHFFFAOYSA-N 3-[4-chloro-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]propane-1,2-diol Chemical compound C12=C(Cl)N=CN=C2N(CC(O)CO)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 IALBWOKSRZOBDJ-UHFFFAOYSA-N 0.000 description 1
- IWPULBFCJIKASE-UHFFFAOYSA-N 4,4-dimethyl-1-(4-phenoxyphenyl)pentan-1-one;hydrochloride Chemical compound Cl.C1=CC(C(=O)CCC(C)(C)C)=CC=C1OC1=CC=CC=C1 IWPULBFCJIKASE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VSFXNRGZTIKUPB-UHFFFAOYSA-N 4-[4-(4-amino-7-tert-butyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound N1=CN=C(N)C2=C1C(C(C)(C)C)CN2C(C=C1)=CC=C1OC1=CC=C(O)C=C1 VSFXNRGZTIKUPB-UHFFFAOYSA-N 0.000 description 1
- YAUXUMSQGNPGQC-UHFFFAOYSA-N 4-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C(O)C=C1 YAUXUMSQGNPGQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DCRHNWDPEHEXAI-UHFFFAOYSA-N 4-amino-7-tert-butyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-6-ol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C(O)=C1C(C=C1)=CC=C1OC1=CC=CC=C1 DCRHNWDPEHEXAI-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- PTCPUGKKWNMITF-UHFFFAOYSA-N 4-chloro-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1F PTCPUGKKWNMITF-UHFFFAOYSA-N 0.000 description 1
- GVFPGTNGIVPDPU-UHFFFAOYSA-N 4-chloro-7-cyclopentyl-5-(2-phenoxyphenyl)pyrrolo[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2N(C2CCCC2)C=C1C1=CC=CC=C1OC1=CC=CC=C1 GVFPGTNGIVPDPU-UHFFFAOYSA-N 0.000 description 1
- WCPHOIPVDSMEID-UHFFFAOYSA-N 4-cyclopentyl-5-(3-phenoxyphenyl)-1,7-dihydropyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)(C3CCCC3)NC=NC=2NC=C1C(C=1)=CC=CC=1OC1=CC=CC=C1 WCPHOIPVDSMEID-UHFFFAOYSA-N 0.000 description 1
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 1
- FIXIQTLWTFUPFK-UHFFFAOYSA-N 4-n-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-1-n-methylbenzene-1,4-diamine Chemical compound C1=CC(NC)=CC=C1NC(C=C1OC)=CC=C1C1=CN(C(C)(C)C)C2=NC=NC(N)=C12 FIXIQTLWTFUPFK-UHFFFAOYSA-N 0.000 description 1
- BTYLOGUNBWCOBV-UHFFFAOYSA-N 4-n-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-1-n-methylbenzene-1,4-diamine Chemical compound C1=CC(NC)=CC=C1NC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 BTYLOGUNBWCOBV-UHFFFAOYSA-N 0.000 description 1
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 1
- SGMDOGYAVIXLQC-UHFFFAOYSA-N 5-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-(3-chlorophenoxy)phenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1O)=CC=C1OC1=CC=CC(Cl)=C1 SGMDOGYAVIXLQC-UHFFFAOYSA-N 0.000 description 1
- SIGWMCFGIFVKPI-UHFFFAOYSA-N 5-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-phenoxyphenol Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1O)=CC=C1OC1=CC=CC=C1 SIGWMCFGIFVKPI-UHFFFAOYSA-N 0.000 description 1
- IOVZQRIKFGCKNR-UHFFFAOYSA-N 5-(4-phenoxyphenyl)-7-(2-phenyl-1,3-dioxan-5-yl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2COC(OC2)C=2C=CC=CC=2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 IOVZQRIKFGCKNR-UHFFFAOYSA-N 0.000 description 1
- GTLYPMCHYLJPTD-UHFFFAOYSA-N 5-(4-phenoxyphenyl)-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 GTLYPMCHYLJPTD-UHFFFAOYSA-N 0.000 description 1
- OBMGVMWHMBYZJC-UHFFFAOYSA-N 5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine;hydrobromide Chemical compound Br.C1=2C(N)=NC=NC=2NC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 OBMGVMWHMBYZJC-UHFFFAOYSA-N 0.000 description 1
- WEVLMNXKWWNNEE-UHFFFAOYSA-N 5-[4-(4-bromophenoxy)phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C(Br)C=C1 WEVLMNXKWWNNEE-UHFFFAOYSA-N 0.000 description 1
- RDCVXFCXAMXWDG-UHFFFAOYSA-N 5-[4-(5-chloro-2-nitrophenoxy)phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC(Cl)=CC=C1[N+]([O-])=O RDCVXFCXAMXWDG-UHFFFAOYSA-N 0.000 description 1
- VPDWAEBGKFDQTQ-UHFFFAOYSA-N 5-[4-(benzenesulfonyl)phenyl]-7-tert-butylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 VPDWAEBGKFDQTQ-UHFFFAOYSA-N 0.000 description 1
- GHYZIXDKAPMFCS-UHFFFAOYSA-N 5-fluoro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1[N+]([O-])=O GHYZIXDKAPMFCS-UHFFFAOYSA-N 0.000 description 1
- ASZFCDOTGITCJI-UHFFFAOYSA-N 6-oxabicyclo[3.1.0]hex-2-ene Chemical compound C1C=CC2OC12 ASZFCDOTGITCJI-UHFFFAOYSA-N 0.000 description 1
- GJEZBVHHZQAEDB-UHFFFAOYSA-N 6-oxabicyclo[3.1.0]hexane Chemical compound C1CCC2OC21 GJEZBVHHZQAEDB-UHFFFAOYSA-N 0.000 description 1
- NKRZPEDCHVVFBV-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(CC(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 NKRZPEDCHVVFBV-UHFFFAOYSA-N 0.000 description 1
- NIYBFYOEORXXTQ-UHFFFAOYSA-N 7-butyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(CCCC)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 NIYBFYOEORXXTQ-UHFFFAOYSA-N 0.000 description 1
- ZQMPTVSCDWLOLC-UHFFFAOYSA-N 7-methyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 ZQMPTVSCDWLOLC-UHFFFAOYSA-N 0.000 description 1
- LEAHJDMQYBZZGE-UHFFFAOYSA-N 7-tert-butyl-5-(2-chloro-4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)Cl)=CC=C1OC1=CC=CC=C1 LEAHJDMQYBZZGE-UHFFFAOYSA-N 0.000 description 1
- BNEWOKNJSGNELA-UHFFFAOYSA-N 7-tert-butyl-5-(2-methoxy-4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C(OC)=CC=1OC1=CC=CC=C1 BNEWOKNJSGNELA-UHFFFAOYSA-N 0.000 description 1
- CDYVIWXTUJTTNA-UHFFFAOYSA-N 7-tert-butyl-5-(2-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C1=CC=CC=C1OC1=CC=CC=C1 CDYVIWXTUJTTNA-UHFFFAOYSA-N 0.000 description 1
- QVXCMWDEWYROOR-UHFFFAOYSA-N 7-tert-butyl-5-(3-methoxy-4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=CC=C1OC1=CC=CC=C1 QVXCMWDEWYROOR-UHFFFAOYSA-N 0.000 description 1
- QFFYYQQIOGHRFZ-UHFFFAOYSA-N 7-tert-butyl-5-(3-methyl-4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=CC=C1OC1=CC=CC=C1 QFFYYQQIOGHRFZ-UHFFFAOYSA-N 0.000 description 1
- FYSSODXXQJTAER-UHFFFAOYSA-N 7-tert-butyl-5-(3-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=1)=CC=CC=1OC1=CC=CC=C1 FYSSODXXQJTAER-UHFFFAOYSA-N 0.000 description 1
- UGTRJCYKIPJAHF-UHFFFAOYSA-N 7-tert-butyl-5-[2-chloro-4-(4-chlorophenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C(=C1)Cl)=CC=C1OC1=CC=C(Cl)C=C1 UGTRJCYKIPJAHF-UHFFFAOYSA-N 0.000 description 1
- GBNOVMOIPFSUDV-UHFFFAOYSA-N 7-tert-butyl-5-[3-chloro-4-(3-chlorophenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1Cl)=CC=C1OC1=CC=CC(Cl)=C1 GBNOVMOIPFSUDV-UHFFFAOYSA-N 0.000 description 1
- RYBIQZCRZRDGAS-UHFFFAOYSA-N 7-tert-butyl-5-[3-methoxy-4-(3-methylphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=CC=C1OC1=CC=CC(C)=C1 RYBIQZCRZRDGAS-UHFFFAOYSA-N 0.000 description 1
- DSEOXMKMHSTLGC-UHFFFAOYSA-N 7-tert-butyl-5-[3-methyl-4-(3-methylphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC=CC(OC=2C(=CC(=CC=2)C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C)=C1 DSEOXMKMHSTLGC-UHFFFAOYSA-N 0.000 description 1
- HMCARUYMUGYRHI-UHFFFAOYSA-N 7-tert-butyl-5-[4-(2-chlorophenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1Cl HMCARUYMUGYRHI-UHFFFAOYSA-N 0.000 description 1
- BTBGEJOUEMJGTG-UHFFFAOYSA-N 7-tert-butyl-5-[4-(2-methoxyphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 BTBGEJOUEMJGTG-UHFFFAOYSA-N 0.000 description 1
- YITGAIYDCLPMAU-UHFFFAOYSA-N 7-tert-butyl-5-[4-(2-methylphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 YITGAIYDCLPMAU-UHFFFAOYSA-N 0.000 description 1
- RULMTNSIRLGMCL-UHFFFAOYSA-N 7-tert-butyl-5-[4-(3-chlorophenoxy)-2-methylphenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C(C)=CC=1OC1=CC=CC(Cl)=C1 RULMTNSIRLGMCL-UHFFFAOYSA-N 0.000 description 1
- GQPJATNKADCJNT-UHFFFAOYSA-N 7-tert-butyl-5-[4-(3-methoxyphenoxy)-3-methylphenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(OC=2C(=CC(=CC=2)C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C)=C1 GQPJATNKADCJNT-UHFFFAOYSA-N 0.000 description 1
- IVHZUGPRQMQRGV-UHFFFAOYSA-N 7-tert-butyl-5-[4-(3-methylphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC=CC(OC=2C=CC(=CC=2)C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=C1 IVHZUGPRQMQRGV-UHFFFAOYSA-N 0.000 description 1
- NJMJETJPNGEOHH-UHFFFAOYSA-N 7-tert-butyl-5-[4-(4-methoxyphenoxy)phenyl]-1h-pyrrolo[2,3-d]pyrimidine-4,4-diamine Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C=2C=3C(N)(N)N=CNC=3N(C=2)C(C)(C)C)C=C1 NJMJETJPNGEOHH-UHFFFAOYSA-N 0.000 description 1
- NJSMJBCABAFTHE-UHFFFAOYSA-N 7-tert-butyl-5-[4-(4-methoxyphenoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 NJSMJBCABAFTHE-UHFFFAOYSA-N 0.000 description 1
- FKBDYMVMAZFAFL-UHFFFAOYSA-N 7-tert-butyl-5-[4-[[4-(methylamino)phenyl]methyl]phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(NC)=CC=C1CC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 FKBDYMVMAZFAFL-UHFFFAOYSA-N 0.000 description 1
- QDAFLAVBAXTUQD-UHFFFAOYSA-N 7-tert-butyl-6-chloro-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C(Cl)=C1C(C=C1)=CC=C1OC1=CC=CC=C1 QDAFLAVBAXTUQD-UHFFFAOYSA-N 0.000 description 1
- MGDRFQIBJWGHOQ-UHFFFAOYSA-N 7-tert-butyl-6-methyl-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C(C)=C1C(C=C1)=CC=C1OC1=CC=CC=C1 MGDRFQIBJWGHOQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010076278 Adenosine kinase Proteins 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- GNRVUEAKPMMKEH-UHFFFAOYSA-N NC=1C2=C(N=CN1)N(C=C2C2=CC=C(C=C2)OC2=CC=CC=C2)C(C)(C)C.N2=CN=C(C=C2)N Chemical compound NC=1C2=C(N=CN1)N(C=C2C2=CC=C(C=C2)OC2=CC=CC=C2)C(C)(C)C.N2=CN=C(C=C2)N GNRVUEAKPMMKEH-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- WJUNAUHPHRBPNV-UHFFFAOYSA-N [4-(2-methoxyphenoxy)phenyl]boronic acid Chemical compound COC1=CC=CC=C1OC1=CC=C(B(O)O)C=C1 WJUNAUHPHRBPNV-UHFFFAOYSA-N 0.000 description 1
- 108700025690 abl Genes Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- OKWOKHLXDJXLNZ-UHFFFAOYSA-N ethyl 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-(3-chlorophenoxy)benzoate Chemical compound C=1C=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C(C(=O)OCC)=CC=1OC1=CC=CC(Cl)=C1 OKWOKHLXDJXLNZ-UHFFFAOYSA-N 0.000 description 1
- GHFQEFZKILBJDF-UHFFFAOYSA-N ethyl 2-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-5-phenoxybenzoate Chemical compound C=1C=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C(C(=O)OCC)=CC=1OC1=CC=CC=C1 GHFQEFZKILBJDF-UHFFFAOYSA-N 0.000 description 1
- HQVRYUZYVFRYTD-UHFFFAOYSA-N ethyl 2-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 HQVRYUZYVFRYTD-UHFFFAOYSA-N 0.000 description 1
- RKMUWCJOBOWDKN-UHFFFAOYSA-N ethyl 5-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-(3-chlorophenoxy)benzoate Chemical compound CCOC(=O)C1=CC(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=CC=C1OC1=CC=CC(Cl)=C1 RKMUWCJOBOWDKN-UHFFFAOYSA-N 0.000 description 1
- ZKVOLMCBVUYOEQ-UHFFFAOYSA-N ethyl 5-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-phenoxybenzoate Chemical compound CCOC(=O)C1=CC(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)=CC=C1OC1=CC=CC=C1 ZKVOLMCBVUYOEQ-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012336 iodinating agent Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- FGNDBHRKHHZLFZ-UHFFFAOYSA-N methyl 4-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C(C)C)C=2)C=C1 FGNDBHRKHHZLFZ-UHFFFAOYSA-N 0.000 description 1
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- YOXWOXDQACBPEQ-UHFFFAOYSA-N n-(2-fluoro-5-nitrophenyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC([N+]([O-])=O)=CC=C1F YOXWOXDQACBPEQ-UHFFFAOYSA-N 0.000 description 1
- PXJGUIPZTSDKMY-UHFFFAOYSA-N n-(2-fluoro-5-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC([N+]([O-])=O)=CC=C1F PXJGUIPZTSDKMY-UHFFFAOYSA-N 0.000 description 1
- STOAGEBURGENGQ-UHFFFAOYSA-N n-(4-hydroxyphenyl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=C(O)C=C1 STOAGEBURGENGQ-UHFFFAOYSA-N 0.000 description 1
- OMTRYQCTEWXIAE-UHFFFAOYSA-N n-[2-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-5-nitrophenyl]acetamide Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1NC(C)=O OMTRYQCTEWXIAE-UHFFFAOYSA-N 0.000 description 1
- NWZQESYBXWEOTK-UHFFFAOYSA-N n-[2-[4-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-5-nitrophenyl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC([N+]([O-])=O)=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3NC=2)C=C1 NWZQESYBXWEOTK-UHFFFAOYSA-N 0.000 description 1
- IZZRYPGIYWRQCJ-UHFFFAOYSA-N n-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxyphenyl]benzenesulfonamide Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C(C=C1O)=CC=C1NS(=O)(=O)C1=CC=CC=C1 IZZRYPGIYWRQCJ-UHFFFAOYSA-N 0.000 description 1
- PYGPUAIMCXXAHV-UHFFFAOYSA-N n-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzamide Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C3CCCC3)C=2)=CC=C1NC(=O)C1=CC=CC=C1 PYGPUAIMCXXAHV-UHFFFAOYSA-N 0.000 description 1
- NNPZHAVLXZLGRT-UHFFFAOYSA-N n-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzenesulfonamide Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C3CCCC3)C=2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 NNPZHAVLXZLGRT-UHFFFAOYSA-N 0.000 description 1
- NYROJQHEZOWWIV-UHFFFAOYSA-N n-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]benzamide Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 NYROJQHEZOWWIV-UHFFFAOYSA-N 0.000 description 1
- CZHQSLKVMSAZMI-UHFFFAOYSA-N n-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxyphenyl]naphthalene-2-sulfonamide Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1O)=CC=C1NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 CZHQSLKVMSAZMI-UHFFFAOYSA-N 0.000 description 1
- KIMUSMGBNNQZHJ-UHFFFAOYSA-N n-[4-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1OC1=CC=C(C=2C3=C(N)N=CN=C3N(C=2)C(C)(C)C)C=C1 KIMUSMGBNNQZHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- VFSBNNSFEZHDPI-UHFFFAOYSA-N oxalic acid;1-(4-phenoxyphenyl)-2-(propan-2-ylamino)ethanone Chemical compound OC(=O)C(O)=O.C1=CC(C(=O)CNC(C)C)=CC=C1OC1=CC=CC=C1 VFSBNNSFEZHDPI-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- YUTHHUZKXISHJH-UHFFFAOYSA-N phenyl n-[4-(4-amino-7-tert-butylpyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxyphenyl]carbamate Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)C=C1C(C=C1O)=CC=C1NC(=O)OC1=CC=CC=C1 YUTHHUZKXISHJH-UHFFFAOYSA-N 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- QHBUOTIIVXFTLH-UHFFFAOYSA-N tert-butyl n-(2-methoxy-4-trimethylstannylphenyl)carbamate Chemical compound COC1=CC([Sn](C)(C)C)=CC=C1NC(=O)OC(C)(C)C QHBUOTIIVXFTLH-UHFFFAOYSA-N 0.000 description 1
- CBDHGBOZFSYMEC-UHFFFAOYSA-N tert-butyl n-[4-(4-chloro-7-cyclopentyl-1h-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methoxyphenyl]carbamate Chemical compound C1=C(NC(=O)OC(C)(C)C)C(OC)=CC(C2(Cl)C3=C(N(C=C3)C3CCCC3)NC=N2)=C1 CBDHGBOZFSYMEC-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4083697P | 1997-03-19 | 1997-03-19 | |
PCT/EP1998/001357 WO1998041525A1 (en) | 1997-03-19 | 1998-03-09 | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SK125999A3 true SK125999A3 (en) | 2000-05-16 |
Family
ID=21913242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1259-99A SK125999A3 (en) | 1997-03-19 | 1998-03-09 | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
Country Status (23)
Country | Link |
---|---|
US (1) | US6001839A (tr) |
EP (1) | EP0970084B1 (tr) |
JP (1) | JP2001516353A (tr) |
KR (1) | KR20000076426A (tr) |
CN (1) | CN1134439C (tr) |
AT (1) | ATE242245T1 (tr) |
AU (1) | AU748884B2 (tr) |
BG (1) | BG64282B1 (tr) |
BR (1) | BR9808281A (tr) |
CA (1) | CA2283961A1 (tr) |
DE (1) | DE69815317T2 (tr) |
DK (1) | DK0970084T3 (tr) |
ES (1) | ES2202827T3 (tr) |
HU (1) | HUP0001507A3 (tr) |
ID (1) | ID24653A (tr) |
IL (1) | IL131582A0 (tr) |
NO (1) | NO313962B1 (tr) |
NZ (1) | NZ337529A (tr) |
PL (1) | PL335685A1 (tr) |
PT (1) | PT970084E (tr) |
SK (1) | SK125999A3 (tr) |
TR (1) | TR199902301T2 (tr) |
WO (1) | WO1998041525A1 (tr) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
AU760020B2 (en) * | 1998-08-31 | 2003-05-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
JP2002526500A (ja) * | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6265403B1 (en) * | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
CZ2002934A3 (cs) * | 1999-09-17 | 2002-07-17 | Abbott Gmbh & Co. Kg | Inhibitory kinázy jako terapeutická činidla |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
EP1268549A2 (en) * | 2000-03-29 | 2003-01-02 | Knoll GmbH | Method of identifying inhibitors of tie-2 |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
KR100403860B1 (ko) * | 2000-12-27 | 2003-11-01 | 엘지전자 주식회사 | 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법 |
AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
IL159506A0 (en) * | 2001-06-23 | 2004-06-01 | Aventis Pharma Inc | Pyrrolopyrimidines as protein kinase inhibitors |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
WO2003002107A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
EP1401413B1 (en) | 2001-06-29 | 2006-11-22 | AB Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
CA2452368A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
JP2004536097A (ja) * | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
WO2003002105A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
ATE343415T1 (de) * | 2001-06-29 | 2006-11-15 | Ab Science | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen |
GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
JP2005508904A (ja) * | 2001-09-11 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体 |
US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
KR20050067383A (ko) | 2002-08-06 | 2005-07-01 | 아스트라제네카 아베 | Tie2(tek) 활성을 갖는 축합 피리딘 및 피리미딘 |
UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
WO2004100947A2 (en) * | 2003-05-06 | 2004-11-25 | Smithkline Beecham Corporation | Novel chemical compounds |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
WO2005047289A1 (en) * | 2003-11-17 | 2005-05-26 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
EP1730148A4 (en) * | 2004-02-03 | 2009-08-19 | Abbott Lab | USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS |
GB0403606D0 (en) * | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
WO2005116035A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
BRPI0606281A2 (pt) * | 2005-03-17 | 2009-06-09 | Novartis Ag | compostos orgánicos |
SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
EP1951724B1 (en) * | 2005-11-17 | 2011-04-27 | OSI Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
WO2007067781A2 (en) * | 2005-12-08 | 2007-06-14 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
TW200806641A (en) * | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
DK2004654T3 (da) * | 2006-04-04 | 2013-07-22 | Univ California | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
EP2201840B1 (en) | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
EP1969934A1 (de) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide |
EP2954900A1 (en) * | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
WO2009117482A1 (en) * | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
ES2570429T3 (es) * | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CA3113343A1 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
JP2014501790A (ja) | 2011-01-10 | 2014-01-23 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | イソキノリノンの調製方法及びイソキノリノンの固体形態 |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
CN103534257A (zh) * | 2011-04-05 | 2014-01-22 | 辉瑞有限公司 | 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN104470515B (zh) * | 2012-05-03 | 2016-12-07 | 圣路易斯药学院 | 用于增加神经营养肽的组合物和方法 |
KR20190040370A (ko) | 2012-06-04 | 2019-04-17 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CN103333096A (zh) * | 2013-06-25 | 2013-10-02 | 苏州大学 | 一种化学选择性制备多功能吡咯衍生物的新方法 |
EA201690618A1 (ru) | 2013-09-30 | 2016-09-30 | Фармасайкликс Элэлси | Ингибиторы тирозинкиназы брутона |
PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9533991B2 (en) | 2014-08-01 | 2017-01-03 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
EP3334430A4 (en) * | 2015-08-13 | 2019-02-06 | San Diego State University Foundation | ATROPISOMERISM FOR INCREASED KINASE HEMMER ELECTIVITY |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2753520C2 (ru) | 2016-06-21 | 2021-08-17 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы |
SG10201912456RA (en) | 2016-06-24 | 2020-02-27 | Infinity Pharmaceuticals Inc | Combination therapies |
PT4039675T (pt) | 2017-04-18 | 2024-09-16 | Eli Lilly And Company | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo |
CA3102129A1 (en) | 2018-06-21 | 2019-12-26 | Cellestia Biotech Ag | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts |
CN112262136B (zh) * | 2018-08-22 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体 |
SG11202110545TA (en) * | 2019-04-10 | 2021-10-28 | Cellestia Biotech Ag | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
AU2020274083A1 (en) | 2019-05-13 | 2021-11-18 | D.E. Shaw Research, Llc | FGFR inhibitors and methods of use thereof |
CN110483523B (zh) * | 2019-08-27 | 2022-11-22 | 药雅科技(上海)有限公司 | 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
US20220356186A1 (en) * | 2019-08-29 | 2022-11-10 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
TW202233625A (zh) * | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Fgfr抑制劑及其製造及使用方法 |
WO2023046117A1 (en) * | 2021-09-23 | 2023-03-30 | 3H Pharmaceuticals Co., Ltd. | Fgfr inhibitors and methods of use thereof |
CN118369322A (zh) * | 2021-12-06 | 2024-07-19 | 英矽智能科技(上海)有限公司 | 取代的单环或双环杂环化合物,其制法与医药上的用途 |
CN116903628A (zh) * | 2022-04-20 | 2023-10-20 | 深圳福沃药业有限公司 | Fgfr2抑制剂及使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0766684A4 (en) * | 1994-06-09 | 1997-07-16 | Smithkline Beecham Corp | ENDOTHELINE RECEPTOR ANTAGONISTS |
CN1046731C (zh) * | 1994-09-29 | 1999-11-24 | 诺瓦蒂斯有限公司 | 吡咯并[2,3-d]嘧啶类化合物及其应用 |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CH690773A5 (de) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
AU1794697A (en) * | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
BR9709443B1 (pt) * | 1996-03-15 | 2009-05-05 | n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas. |
-
1998
- 1998-03-09 KR KR1019997008530A patent/KR20000076426A/ko not_active Application Discontinuation
- 1998-03-09 CN CN98805152.4A patent/CN1134439C/zh not_active Expired - Fee Related
- 1998-03-09 AU AU68293/98A patent/AU748884B2/en not_active Ceased
- 1998-03-09 AT AT98913690T patent/ATE242245T1/de active
- 1998-03-09 WO PCT/EP1998/001357 patent/WO1998041525A1/en not_active Application Discontinuation
- 1998-03-09 ES ES98913690T patent/ES2202827T3/es not_active Expired - Lifetime
- 1998-03-09 EP EP98913690A patent/EP0970084B1/en not_active Expired - Lifetime
- 1998-03-09 IL IL13158298A patent/IL131582A0/xx unknown
- 1998-03-09 JP JP54009098A patent/JP2001516353A/ja not_active Ceased
- 1998-03-09 DK DK98913690T patent/DK0970084T3/da active
- 1998-03-09 BR BR9808281-7A patent/BR9808281A/pt not_active IP Right Cessation
- 1998-03-09 HU HU0001507A patent/HUP0001507A3/hu unknown
- 1998-03-09 TR TR1999/02301T patent/TR199902301T2/tr unknown
- 1998-03-09 PL PL98335685A patent/PL335685A1/xx unknown
- 1998-03-09 SK SK1259-99A patent/SK125999A3/sk unknown
- 1998-03-09 CA CA002283961A patent/CA2283961A1/en not_active Abandoned
- 1998-03-09 ID IDW991048A patent/ID24653A/id unknown
- 1998-03-09 NZ NZ337529A patent/NZ337529A/xx unknown
- 1998-03-09 PT PT98913690T patent/PT970084E/pt unknown
- 1998-03-09 DE DE69815317T patent/DE69815317T2/de not_active Expired - Lifetime
- 1998-03-17 US US09/042,702 patent/US6001839A/en not_active Expired - Lifetime
-
1999
- 1999-09-17 NO NO19994509A patent/NO313962B1/no not_active IP Right Cessation
- 1999-10-07 BG BG103785A patent/BG64282B1/bg unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0001507A2 (hu) | 2000-10-28 |
PL335685A1 (en) | 2000-05-08 |
JP2001516353A (ja) | 2001-09-25 |
BG64282B1 (bg) | 2004-08-31 |
US6001839A (en) | 1999-12-14 |
NZ337529A (en) | 2000-10-27 |
WO1998041525A1 (en) | 1998-09-24 |
DK0970084T3 (da) | 2003-09-29 |
EP0970084A1 (en) | 2000-01-12 |
DE69815317D1 (de) | 2003-07-10 |
ID24653A (id) | 2000-07-27 |
KR20000076426A (ko) | 2000-12-26 |
AU6829398A (en) | 1998-10-12 |
BG103785A (en) | 2000-06-30 |
ES2202827T3 (es) | 2004-04-01 |
CN1259950A (zh) | 2000-07-12 |
AU748884B2 (en) | 2002-06-13 |
BR9808281A (pt) | 2000-05-16 |
EP0970084B1 (en) | 2003-06-04 |
IL131582A0 (en) | 2001-01-28 |
NO994509D0 (no) | 1999-09-17 |
CN1134439C (zh) | 2004-01-14 |
NO313962B1 (no) | 2003-01-06 |
DE69815317T2 (de) | 2005-04-07 |
ATE242245T1 (de) | 2003-06-15 |
NO994509L (no) | 1999-09-17 |
TR199902301T2 (tr) | 1999-12-21 |
PT970084E (pt) | 2003-10-31 |
CA2283961A1 (en) | 1998-09-24 |
HUP0001507A3 (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK125999A3 (en) | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors | |
US8329716B2 (en) | Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors | |
CA2692859C (en) | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | |
JP5400626B2 (ja) | 置換イミダゾおよびトリアゾロピリミジン類 | |
JP5507546B2 (ja) | 置換イミダゾ−およびトリアゾロピリミジン類、イミダゾ−およびピラゾロピラジン類およびイミダゾトリアジン類 | |
US20080287468A1 (en) | Purine and imidazopyridine derivatives for immunosuppression | |
US20010025043A1 (en) | New pharmaceutical active compounds | |
US20030191307A1 (en) | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | |
NZ505079A (en) | Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists | |
CA2669686A1 (en) | 7-substituted purine derivatives for immunosuppression | |
TW200831104A (en) | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | |
TW200304818A (en) | Kinase inhibitors | |
TW200837064A (en) | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression | |
KR20080081177A (ko) | 야누스 키나아제 억제제인 술폰아미도아닐린 유도체 | |
KR20190002468A (ko) | N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태 | |
EP2521726B1 (fr) | Dérivés de 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine comme inhibiteurs de kinases camkii pour le traitement de maladies cardiovasculaires | |
JP2011506364A (ja) | トリアゾロトリアジンおよびトリアゾロピラジンおよびそれらの使用 | |
SK286461B6 (sk) | [1,5-a]-Pyrazolo-1,3,5-triazíny, ich použitie a farmaceutické kompozície na ich báze | |
MXPA99008171A (es) | Agentes terapeuticos | |
CZ328399A3 (cs) | Derivát pyrrolo[2,3d]pyrimidinu, způsob jeho přípravy a jeho použití | |
TW201004620A (en) | Heterocyclic compound and use thereof |